Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	76
Overall Study	STARTED	Atacicept 150 mg With Loading Dose	78
Overall Study	STARTED	Atacicept 150 mg Without Loading Dose	78
Overall Study	STARTED	Adalimumab	79
Overall Study	COMPLETED	Placebo	69
Overall Study	COMPLETED	Atacicept 150 mg With Loading Dose	73
Overall Study	COMPLETED	Atacicept 150 mg Without Loading Dose	70
Overall Study	COMPLETED	Adalimumab	75
Overall Study	NOT COMPLETED	Placebo	7
Overall Study	NOT COMPLETED	Atacicept 150 mg With Loading Dose	5
Overall Study	NOT COMPLETED	Atacicept 150 mg Without Loading Dose	8
Overall Study	NOT COMPLETED	Adalimumab	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00595413/flow